A Randomized, Open-Label, Phase 2 Trial of CMB305 (Sequentially Administered LV305 and G305) and Atezolizumab in Patients With Locally Advanced, Relapsed, or Metastatic Sarcoma Expressing NY-ESO-1
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 04 Jul 2018
At a glance
- Drugs CMB 305 (Primary) ; Atezolizumab
- Indications Liposarcoma; Soft tissue sarcoma; Synovial sarcoma
- Focus Therapeutic Use
- Sponsors Immune Design
- 26 Jun 2018 Planned End Date changed from 1 Jul 2019 to 1 Mar 2019.
- 26 Jun 2018 Planned primary completion date changed from 1 Mar 2017 to 1 Dec 2018.
- 01 Nov 2017 According to an Immune Design media release, data from the study will be presented at the Connective Tissue Oncology Society (CTOS) Annual Meeting 2017.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History